JNJ and AbbVie plan to expedite approvals for some blood cancer treatments in the US

Published Date: 11 Apr 2023

AbbVie and partner Johnson & Johnson intend to voluntarily withdraw the accelerated approval of Imbruvica in the US for patients with certain types of blood cancer.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

4.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot